CAR T-cell Therapy | Specialty

Dr. Gauthier on Potential for CAR T Cells in CLL

December 11th 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

Dr. Madduri on Treatment After CAR T Cells in Myeloma

December 11th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.

Dr. Pulsipher on MRD in Pediatric Patients Treated With CAR T Cells

December 7th 2018

Michael Pulsipher, MD, director of cellular therapy and stem cell transplantation, professor of pediatrics, USC Keck School of Medicine, discusses the role of MRD testing in pediatric patients treated with CAR T-cell therapy.

Axi-Cel Efficacy Persists at 2-Year Assessment for Large B-Cell Lymphoma

December 4th 2018

Axicabtagene ciloleucel elicited a 2-year overall survival rate of 51% in patients with refractory large B cell lymphoma, representing a clear plateau in the survival curve.

Liso-Cel Demonstrates Durable Responses in Heavily Pretreated, High-Risk CLL

December 3rd 2018

Lisocabtagene maraleucel appeared tolerable and induced an 81.3% best overall response rate and 43.8% complete response rate in heavily pretreated, high-risk patients with chronic lymphocytic leukemia who previously received ibrutinib.

Checkpoint Inhibition May Improve CAR T-Cell Persistence

December 2nd 2018

Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.

Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL

December 2nd 2018

Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.

Novel T-Cell Therapies Make Inroads Into Solid Tumors

November 28th 2018

Although CAR T-cell therapies have proved successful in certain hematologic malignancies, efforts to employ similar strategies in solid tumors have been challenging. Investigators are working on different forms of adoptive cell therapy in solid tumors and early signs are promising.

Dr. Boccia on Managing Adverse Events With CAR T-Cell Therapy

November 17th 2018

Ralph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.

Dr. Goy on Need for Payment Model for CAR T-Cell Therapy

November 17th 2018

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center at Hackensack University Medical Center, discusses the affordability of cancer treatment breakthroughs such as chimeric antigen receptor T-cell therapy.

Dr. Chari on Impact of CAR T Cells in Myeloma

November 16th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of CAR T-cell therapy in myeloma.

CAR T-Cell Therapies Moving to Outpatient Setting

November 8th 2018

The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year.

Dr. Ghobadi on the Potential Development of CAR T Cells in Solid Tumors

November 8th 2018

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Dr. Smith Discusses CAR T Cell Persistence in Myeloma

November 2nd 2018

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

The Impact of Precision Medicine in Oncology

October 30th 2018

Ryan Bookout, PharmD, president, Hematology/Oncology Pharmacy Association, clinical pharmacist, Moffitt Cancer Center, discusses the impact of recent advances and precision medicine in oncology.

Future Directions for CAR-T Therapy

October 29th 2018

Expanding the Role of CAR T in non-Hodgkin Lymphoma

October 29th 2018

CAR-T Post-Infusion Care, Financial Considerations, and Data Management

October 29th 2018

The Production of CAR T Cells for non-Hodgkin Lymphoma

October 29th 2018

The Workflow of CAR-T Administration

October 29th 2018